SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...
The appetites of biotech investors for companies expanding in artificial intelligence show no signs of slowing any time soon, as reflected by the stock surge enjoyed by Recursion Pharmaceuticals (RXRX ...
Good morning and [Technical Difficulty] Healthcare Conference [Technical Difficulty] love to have you in Miami. [Technical Difficulty]. I'm Mani Foroohar, senior analyst, genetic medicines here at ...
Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results